---
document_datetime: 2025-12-02 06:41:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/qutenza.html
document_name: qutenza.html
version: success
processing_time: 0.1119986
conversion_datetime: 2025-12-28 03:12:25.064232
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Qutenza

[RSS](/en/individual-human-medicine.xml/66466)

##### Authorised

This medicine is authorised for use in the European Union

capsaicin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Qutenza](#news-on)
- [More information on Qutenza](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Qutenza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Qutenza.

Expand section

Collapse section

## What is Qutenza?

Qutenza is a cutaneous patch (a patch that delivers a medicine into the skin). It contains the active substance capsaicin (8%).

## What is Qutenza used for?

Qutenza is used to treat peripheral neuropathic pain (pain that is caused by damage to the nerves) in adults. It can be used alone or together with other medicines for pain.

The medicine can only be obtained with a prescription.

## How is Qutenza used?

Qutenza should be applied by a doctor or by a healthcare professional under the supervision of a doctor. It is applied to the most painful areas of the skin. The painful area should be determined by a doctor and marked on the skin. Qutenza can only be applied to unbroken, non-irritated, dry skin.

Patches can be cut to match the area to cover. No more than four patches should be used on the patient at the same time. Before applying Qutenza, the area may be treated with a local anaesthetic to numb it; this helps to reduce discomfort. Alternatively, medicines for pain may be taken. Qutenza should remain in place for 30 minutes for the feet and 60 minutes for other parts of the body. Once the patch is removed, the area is cleaned using the cleansing gel provided. It may take up to three weeks for Qutenza to have an effect. The treatment may be repeated every three months depending on the patient's symptoms.

Qutenza can cause a burning sensation on the skin. Because of this, healthcare professionals should wear nitrile gloves while applying and removing the patch.

## How does Qutenza work?

The active substance in Qutenza, capsaicin, is a substance normally found in chilli peppers. It stimulates the 'transient receptor potential vanilloid 1' (TRPV1) receptor which is found in the nerves in the skin that detect pain. The rapid release of high doses of capsaicin from Qutenza overstimulates the TRPV1 receptors so they become less sensitive to the stimuli that normally cause neuropathic pain.

## How has Qutenza been studied?

Qutenza has been compared with control patches containing lower amounts of capsaicin (0.04%) in four main studies involving a total of 1,619 adults with moderate to severe neuropathic pain. All of the patients had neuropathic pain due to either post-herpetic neuralgia (pain that occurs in people who have had shingles, an infection caused by the varicella zoster virus) or HIV-associated neuropathy (damage to the nerves caused by HIV infection). A fifth study compared Qutenza with a placebo (dummy) patch in 369 patients with painful peripheral diabetic neuropathy, a form of neuropathic pain associated with diabetes; a supportive study looked at repeated treatment over one year. The main measure of effectiveness in all main studies was the reduction in the 24-hour pain score during an eight- or 12-week period after application of the patch.

## What benefit has Qutenza shown during the studies?

Qutenza was more effective at reducing neuropathic pain than the control patches. In the two studies of patients with post-herpetic neuralgia, the reduction in pain scores after eight weeks was 30 and 32% in patients who were given Qutenza, compared with 20 and 24% in patients who received the control patches. In one of the studies of patients with HIV-associated neuropathy, patients who were given Qutenza experienced a 23% reduction in pain scores after 12 weeks compared with an 11% reduction in patients who were given the control. In the second study of patients with HIV-associated neuropathy, although Qutenza reduced pain by 30% it was not shown to be more effective than the control. In patients with painful peripheral diabetic neuropathy, the reduction in pain score from week 2 to after 8 weeks with Qutenza was about 27% compared with 21% for the placebo. Supportive data showed benefit when Qutenza was repeated over a 1-year period in combination with other treatments.

## What is the risk associated with Qutenza?

The most common side effects with Qutenza (seen in more than 1 patient in 10) are pain and redness at the site of application. For the full list of all side effects and restrictions with Qutenza, see the package leaflet.

## Why has Qutenza been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Qutenza's benefits are greater than its risks and recommended that Qutenza be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Qutenza?

A risk management plan has been developed to ensure that Qutenza is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Qutenza, including the appropriate precautions to be followed by healthcare professionals and patients.

In addition, the company that makes Qutenza will make sure that an educational programme is available for healthcare professionals who will prescribe Qutenza. The programme will include information on how to administer, handle and dispose of Qutenza and on warnings and precautions that should be considered during treatment.

## Other information about Qutenza

The European Commission granted a marketing authorisation valid throughout the European Union for Qutenza on 15 May 2009.

For more information about treatment with Qutenza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Qutenza : EPAR - Summary for the public

English (EN) (75.69 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 08/10/2015

[View](/en/documents/overview/qutenza-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-236)

български (BG) (106.3 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/bg/documents/overview/qutenza-epar-summary-public_bg.pdf)

español (ES) (80.34 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/es/documents/overview/qutenza-epar-summary-public_es.pdf)

čeština (CS) (103.77 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/cs/documents/overview/qutenza-epar-summary-public_cs.pdf)

dansk (DA) (80.98 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/da/documents/overview/qutenza-epar-summary-public_da.pdf)

Deutsch (DE) (82.79 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/de/documents/overview/qutenza-epar-summary-public_de.pdf)

eesti keel (ET) (80.26 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/et/documents/overview/qutenza-epar-summary-public_et.pdf)

ελληνικά (EL) (107.11 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/el/documents/overview/qutenza-epar-summary-public_el.pdf)

français (FR) (83.26 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/fr/documents/overview/qutenza-epar-summary-public_fr.pdf)

hrvatski (HR) (97.96 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/hr/documents/overview/qutenza-epar-summary-public_hr.pdf)

italiano (IT) (79.93 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/it/documents/overview/qutenza-epar-summary-public_it.pdf)

latviešu valoda (LV) (100.24 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/lv/documents/overview/qutenza-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (101.45 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/lt/documents/overview/qutenza-epar-summary-public_lt.pdf)

magyar (HU) (97.92 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/hu/documents/overview/qutenza-epar-summary-public_hu.pdf)

Malti (MT) (104.52 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/mt/documents/overview/qutenza-epar-summary-public_mt.pdf)

Nederlands (NL) (81.13 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/nl/documents/overview/qutenza-epar-summary-public_nl.pdf)

polski (PL) (102.61 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/pl/documents/overview/qutenza-epar-summary-public_pl.pdf)

português (PT) (81.71 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/pt/documents/overview/qutenza-epar-summary-public_pt.pdf)

română (RO) (99.83 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/ro/documents/overview/qutenza-epar-summary-public_ro.pdf)

slovenčina (SK) (103 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/sk/documents/overview/qutenza-epar-summary-public_sk.pdf)

slovenščina (SL) (97 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/sl/documents/overview/qutenza-epar-summary-public_sl.pdf)

Suomi (FI) (80.65 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/fi/documents/overview/qutenza-epar-summary-public_fi.pdf)

svenska (SV) (81.53 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

08/10/2015

[View](/sv/documents/overview/qutenza-epar-summary-public_sv.pdf)

## Product information

Qutenza : EPAR - Product Information

English (EN) (185.47 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 04/12/2023

[View](/en/documents/product-information/qutenza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-880)

български (BG) (209.84 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/bg/documents/product-information/qutenza-epar-product-information_bg.pdf)

español (ES) (201.65 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/es/documents/product-information/qutenza-epar-product-information_es.pdf)

čeština (CS) (190.54 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/cs/documents/product-information/qutenza-epar-product-information_cs.pdf)

dansk (DA) (191.74 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/da/documents/product-information/qutenza-epar-product-information_da.pdf)

Deutsch (DE) (201.54 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/de/documents/product-information/qutenza-epar-product-information_de.pdf)

eesti keel (ET) (174.98 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/et/documents/product-information/qutenza-epar-product-information_et.pdf)

ελληνικά (EL) (214.88 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/el/documents/product-information/qutenza-epar-product-information_el.pdf)

français (FR) (193.76 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/fr/documents/product-information/qutenza-epar-product-information_fr.pdf)

hrvatski (HR) (198.77 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/hr/documents/product-information/qutenza-epar-product-information_hr.pdf)

íslenska (IS) (190.49 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/is/documents/product-information/qutenza-epar-product-information_is.pdf)

italiano (IT) (191.29 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/it/documents/product-information/qutenza-epar-product-information_it.pdf)

latviešu valoda (LV) (179.72 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/lv/documents/product-information/qutenza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (181.94 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/lt/documents/product-information/qutenza-epar-product-information_lt.pdf)

magyar (HU) (193.62 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/hu/documents/product-information/qutenza-epar-product-information_hu.pdf)

Malti (MT) (225 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/mt/documents/product-information/qutenza-epar-product-information_mt.pdf)

Nederlands (NL) (195.55 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/nl/documents/product-information/qutenza-epar-product-information_nl.pdf)

norsk (NO) (200.44 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/no/documents/product-information/qutenza-epar-product-information_no.pdf)

polski (PL) (201.8 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/pl/documents/product-information/qutenza-epar-product-information_pl.pdf)

português (PT) (186.75 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/pt/documents/product-information/qutenza-epar-product-information_pt.pdf)

română (RO) (191.83 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/ro/documents/product-information/qutenza-epar-product-information_ro.pdf)

slovenčina (SK) (202.94 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/sk/documents/product-information/qutenza-epar-product-information_sk.pdf)

slovenščina (SL) (181.67 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/sl/documents/product-information/qutenza-epar-product-information_sl.pdf)

Suomi (FI) (180.72 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/fi/documents/product-information/qutenza-epar-product-information_fi.pdf)

svenska (SV) (184.73 KB - PDF)

**First published:**

16/11/2009

**Last updated:**

04/12/2023

[View](/sv/documents/product-information/qutenza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0062 01/12/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Qutenza : EPAR - All Authorised presentations

English (EN) (12.25 KB - PDF)

**First published:** 09/06/2009

**Last updated:** 08/03/2010

[View](/en/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-215)

български (BG) (77.75 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/bg/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.69 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/es/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (74.25 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/cs/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.46 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/da/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.5 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/de/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.55 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/et/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.21 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/el/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_el.pdf)

français (FR) (12.77 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/fr/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (12.22 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/it/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (76.99 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/lv/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (74.53 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/lt/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (74.11 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/hu/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (77.74 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/mt/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.26 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/nl/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_nl.pdf)

polski (PL) (79.88 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/pl/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.67 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/pt/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_pt.pdf)

română (RO) (73.08 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/ro/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (76.67 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/sk/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (74.64 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/sl/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.35 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/fi/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (12.75 KB - PDF)

**First published:**

09/06/2009

**Last updated:**

08/03/2010

[View](/sv/documents/all-authorised-presentations/qutenza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Qutenza Active substance capsaicin International non-proprietary name (INN) or common name capsaicin Therapeutic area (MeSH) Neuralgia Anatomical therapeutic chemical (ATC) code N01BX04

### Pharmacotherapeutic group

Anesthetics

### Therapeutic indication

Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.

## Authorisation details

EMA product number EMEA/H/C/000909 Marketing authorisation holder

Grunenthal GmbH

Zieglerstrasse 6

Opinion adopted 19/03/2009 Marketing authorisation issued 15/05/2009 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Qutenza : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (180.62 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 04/12/2023

[View](/en/documents/procedural-steps-after/qutenza-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Qutenza-H/C-909-II-0039 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/545605/2015

English (EN) (3.06 MB - PDF)

**First published:** 08/10/2015

**Last updated:** 08/10/2015

[View](/en/documents/variation-report/qutenza-hc-909-ii-0039-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Qutenza

Adopted

Reference Number: EMA/CHMP/442672/2015

English (EN) (67.02 KB - PDF)

**First published:** 24/07/2015

**Last updated:** 24/07/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-qutenza_en.pdf)

## Initial marketing authorisation documents

Qutenza : EPAR - Public assessment report

English (EN) (543.26 KB - PDF)

**First published:** 09/06/2009

**Last updated:** 09/06/2009

[View](/en/documents/assessment-report/qutenza-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Qutenza

Reference Number: EMEA/CHMP/162956/2009

English (EN) (33.03 KB - PDF)

**First published:** 19/03/2009

**Last updated:** 19/03/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-qutenza_en.pdf)

#### News on Qutenza

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2015) 24/07/2015

#### More information on Qutenza

- [Qutenza - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/qutenza)
- [Capsaicin 179 mg cutaneous patch treatment in eldery patients with peripheral localized neuropathic pain - A subgroup analysis of the retrospective CASPAR study to evaluate safety, tolerability and efficacy in daily practice (CASPAGE) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000575)
- [Capsaicin 179 mg cutaneous patch treatment in adult patients with peripheral localized neuropathic pain - A retrospective study to document initial/progressive response and develop a responder profiling algorithm based on the number of treatments in a longitudinal analysis of depersonalized bio-psycho-social real-world data of a subset of the German Pain e-Registry (CASPAR) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000106)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/12/2023

## Share this page

[Back to top](#main-content)